BIOMAT Database Logo BIOMAT Database Logo

Warfarin elimination and responsiveness in patients with renal dysfunction. 1978

A VanPeer, and F Belpaire, and M Bogaert

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007700 Kinetics The rate dynamics in chemical or physical systems.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

A VanPeer, and F Belpaire, and M Bogaert
Warfarin elimination and responsiveness in patients with renal dysfunction.
January 1977, Journal of clinical pharmacology,
A VanPeer, and F Belpaire, and M Bogaert
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction.
June 2020, Blood advances,
A VanPeer, and F Belpaire, and M Bogaert
Cefotetan elimination in patients with varying degrees of renal dysfunction.
January 1983, The Journal of antimicrobial chemotherapy,
A VanPeer, and F Belpaire, and M Bogaert
The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction.
June 1983, The Journal of antimicrobial chemotherapy,
A VanPeer, and F Belpaire, and M Bogaert
Renal Dysfunction Affects Anticoagulation Control With Warfarin and Outcomes in Japanese Elderly Patients With Non-Valvular Atrial Fibrillation.
August 2018, Circulation journal : official journal of the Japanese Circulation Society,
A VanPeer, and F Belpaire, and M Bogaert
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
May 2008, Journal of cardiac failure,
A VanPeer, and F Belpaire, and M Bogaert
Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
March 2017, Journal of the American Heart Association,
A VanPeer, and F Belpaire, and M Bogaert
Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
June 1998, Thrombosis and haemostasis,
A VanPeer, and F Belpaire, and M Bogaert
Influence of renal dysfunction on warfarin plasma protein binding.
October 1976, Journal of clinical pharmacology,
A VanPeer, and F Belpaire, and M Bogaert
Warfarin-induced calciphylaxis in patients with normal renal function.
August 2016, Journal of clinical pharmacy and therapeutics,
Copied contents to your clipboard!